<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407640</url>
  </required_header>
  <id_info>
    <org_study_id>P081223</org_study_id>
    <nct_id>NCT01407640</nct_id>
  </id_info>
  <brief_title>Diagnosis and Physiopathology of Insulin Allergy</brief_title>
  <acronym>Allerdiab</acronym>
  <official_title>Diagnosis and Physiopathology of Insulin Allergy (IA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin allergy (IA) is still observed even with recombinant human insulin and insulin
      analogs.

      Obviously, the usual attitude facing an allergy, i. e. exclusion of the allergen, poses
      problems in face of IA because insulin is often vital for the patient. IA is thus a complex
      situation in which a rigorous diagnostic procedure to identify the exact allergen is
      necessary to propose a therapeutic answer; the purpose of the study is 1/ to validate a
      diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate
      immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phenotype of the patient Investigation of allergy per intradermal testing using a wide range
      of insulin preparations Determination of immunologic and immunogenetic profile particularly
      CD4 + T cells and mast cells
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2012</start_date>
  <completion_date type="Actual">July 27, 2016</completion_date>
  <primary_completion_date type="Actual">July 27, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of cutaneous insulin tests</measure>
    <time_frame>after 36 months</time_frame>
    <description>Response of cutaneous insulin tests in patients with IA (Insulin Allergy) at study completion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenetic of patients with IA (Insulin Allergy)</measure>
    <time_frame>after 36 months</time_frame>
    <description>Immunogenetic of patients with IA (Insulin Allergy) at study completion Determination of insulin epitopes that are involved in IA at study completion Determination of isotypes of anti insulin antibodies and whether specific isotypes are associated with susceptibility / protection at study completion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypersensitivity</condition>
  <condition>Immediate Hypersensitivity</condition>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allergy tests</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allergy tests</intervention_name>
    <description>1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patients aged 18 years old and more with a written informed consent

          -  Experimental group : type 1 or type 2 diabetic patients with insulin allergy based on
             clinical criteria

          -  Active Comparator group: type 1 or type 2 diabetic patients insulin treated without
             insulin allergy

        Exclusion criteria :

          -  Not willing participate

          -  Pregnancy

          -  Age below 18 years

          -  Severe Renal failure

          -  Severe Anaphylactic shock only for the experimental group

          -  No social security overture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnes Sola-Gazagnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Sola-Gazagnes A, Pecquet C, Radermecker R, Piétri L, Elgrably F, Slama G, Sélam JL. Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin. Diabetes Care. 2003 Oct;26(10):2961-2.</citation>
    <PMID>14514615</PMID>
  </reference>
  <reference>
    <citation>Sola-Gazagnes A, Pecquet C. [Allergy to insulin in 2003]. Journ Annu Diabetol Hotel Dieu. 2004:161-79. Review. French.</citation>
    <PMID>15259314</PMID>
  </reference>
  <reference>
    <citation>Sola-Gazagnes A, Pecquet C, M'Bemba J, Larger E, Slama G. Type I and type IV allergy to the insulin analogue detemir. Lancet. 2007 Feb 24;369(9562):637-8.</citation>
    <PMID>17321300</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin allergy</keyword>
  <keyword>adverse drug reaction</keyword>
  <keyword>diabetes</keyword>
  <keyword>type 1 hypersensitivity</keyword>
  <keyword>immediate hypersensitivity</keyword>
  <keyword>type 4 hypersensitivity</keyword>
  <keyword>insulin analogs</keyword>
  <keyword>intradermal testing</keyword>
  <keyword>insulin antibody</keyword>
  <keyword>mast cell</keyword>
  <keyword>CD+ TCELL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypersensitivity, Immediate</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

